Financial Aid Recipients Breaking Funding Rules: Investigation

Many early-career clinical scientists receiving support through the NIH’s Loan Repayment Program have accepted disallowed industry funding, Science reveals.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, KEVINHYDE

A substantial proportion of early-career investigators receiving financial aid from the National Institutes of Health to pay off school debt are violating the program’s rules on industry funding, an investigation by Science has revealed. Of nearly 200 clinical scientists funded by the agency’s Loan Repayment Program (LRP) in the last five years, Science found that more than one-third broke the agency’s rules when they accepted money for consulting or industry work, although the investigation also finds that many recipients may have been unaware that they were doing anything wrong.

“The intent of the LRP should be to assist people who pursue something that is very challenging in academic medicine—building a career that is truly independent of conflicted bodies,” Oregon Health & Science University’s Vinay Prasad, who studies industry influence on medical research, tells Science. He adds that, “for this pattern [of violations] to emerge, many people ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies